Cervical Cancer Therapeutics Pipeline Review, H1 2016 – Review of 70 Companies & Their Drug Profile Activity – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Cervical
Cancer – Pipeline Review, H1 2016″ report to their offering.
This report provides comprehensive information on the therapeutic
development for Cervical Cancer, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Cervical
Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Cervical Cancer Overview
- Therapeutics Development
- Pipeline Products for Cervical Cancer – Overview
- Pipeline Products for Cervical Cancer – Comparative Analysis
- Cervical Cancer – Therapeutics under Development by Companies
-
Cervical Cancer – Therapeutics under Investigation by
Universities/Institutes - Cervical Cancer Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Cervical Cancer – Products under Development by Companies
-
Cervical Cancer – Products under Investigation by
Universities/Institutes - Cervical Cancer – Companies Involved in Therapeutics Development
- 3SBio Inc.
- Admedus Ltd
- Advaxis, Inc.
- Advenchen Laboratories, LLC
- AnGes MG, Inc.
- Antigen Express, Inc.
- Arbor Vita Corporation
- ArQule, Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Azaya Therapeutics, Inc.
- Blirt S.A.
- Bristol-Myers Squibb Company
- Cancer Research Technology Limited
- Cellceutix Corporation
- Chong Kun Dang Pharmaceutical Corp.
- Coherus BioSciences, Inc.
- Critical Outcome Technologies Inc.
- CZ BioMed Corp
- DelMar Pharmaceuticals, Inc.
- Dr. Reddy’s Laboratories Limited
- EirGenix Inc.
- Eisai Co., Ltd.
- Eureka Therapeutics, Inc.
- EyeGene, Inc.
- F. Hoffmann-La Roche Ltd.
- Formune S.L.
- Genexine, Inc.
- Genmab A/S
- Genor BioPharma Co., Ltd.
- Genticel S.A.
- GlaxoSmithKline Plc
- Immunovaccine, Inc.
- ISA Pharmaceuticals B.V.
- Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/zvpzg3/cervical_cancer
About Research and Markets
Research and Markets is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
Contacts
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cervical
Cancer Drugs
